摘要
Abstract
Objective To analyze the clinical effect of Edaravone Dexamethasone in the treatment of acute ischemic stroke(AIS).Methods A total of 40 patients with AIS admitted to the First People's Hospital of Qinzhou from June 2022 to March 2023 were selected as the research objects,and they were divided into the control group(20 cases)and the treatment group(20 cases)according to the random number table method.The control group was treated with Alteplase,while the treatment group was treated with Edaravone Dexamethasone on the basis of the control group.The neurological functions,serum indicators(erythrocyte sedimentation rate[ESR],white blood cell count),inflammatory factors(interleukin-6[IL-6],interleukin-1β[IL-1β],tumor necrosis factor-α[TNF-α],high-sensitivity C-reactive protein[hs-CRP]),prognosis,adverse reactions of the two groups of patients were compared.Results The scores of the National Institutes of Health stroke scale(NIHSS)and the modified Rankin scale(mRS)in the treatment group were lower than those in the control group,and the differences were statistically significant(P＜0.05).The white blood cell count and hs-CRP level in the treatment group were both lower than those in the control group,and the differences were statistically significant(P＜0.05).The levels of IL-6,IL-1β and TNF-α in the treatment group were all lower than those in the control group,and the differences were statistically significant(P＜0.05).There was no statistically significant difference in the ESR levels after treatment between the two groups(P＞0.05).No adverse reactions occurred in either group.Conclusion Edaravone Dexcamphene can achieve significant therapeutic effects in the treatment of AIS.It can inhibit inflammatory responses,promote the recovery of neurological function,and has high safety in medication,with good clinical application prospects.关键词
急性缺血性脑卒中/静脉溶栓/依达拉奉右莰醇/临床效果Key words
Acute ischemic stroke/Intravenous thrombolysis/Edaravone Dexamethasone/Clinical effect分类
医药卫生
